Herantis Pharma is a specialty pharmaceutical company based in Helsinki, Finland. It specializes in drugs for the treatment of dry eye, Parkinson's diseases, amyotrophic lateral sclerosis (ALS) and secondary lymphedema. They are developing selected drug candidates through late preclinical and early clinical stages. Herantis products in pipeline include Cis-UCA eye drops, CDNF for the treatment of Parkinson's Diseases ALS; and Lymfactin, which is in clinical trials for treating breast cancer.